. Author manuscript; available in PMC: 2013 Jul 22.

Published in final edited form as: Curr HIV/AIDS Rep. 2012 Jun;9(2):101–110. doi: 10.1007/s11904-012-0113-0

Table 1.

Summary of clinical trials of treatment of acute HIV with ART

Study	Time to ART from diagnosis	Duration of ART	Outcome, as compared to untreated
Kinloch-De Loes (1995) [34] Placebo-controlled RCT	25 days	24 weeks	Less opportunistic infections during treatment
AZT monotherapy
Niu (1995) [35] Placebo-controlled RCT AZT monotherapy	18 days	24 weeks	Improved CD4+ T cell counts at 1 year after treatment interruption (TI) but no difference in viral load (VL) or clinical events
Hogan, SETPOINT (2011) [36••] RCT	Within 6 months	36 weeks	Delayed time to CD4+ T cell counts ≤ 350 cells/mm³ after TI
3-drug ART
Streeck (2006) [39] Observational prospective	25 days	24 weeks	Improved HIV-specific CD8+ T cell responses, no improved VL for 6 months after TI
3-drug ART
Hecht (2006) [40] Observational prospective	14 days	12 weeks	Decreased VL, improved CD4+ T cell count for 72 weeks after TI
3-drug ART
Fidler (2007) [41] Retrospective	“During primary infection”	12 weeks	Slower CD4+ T-cell decline after TI
3-drug ART
Von Wyl (2011) [42] Observational prospective	16 weeks	18 months	Decreased VL for 1 y but not 3 y after TI
3-drug ART
Grijsen (2011) [37] Randomized 3-arm	“During primary infection”	24 or 60 weeks	Decreased VL and decreased time to start ART 36 wk after TI
3-drug ART
Fidler, SPARTAC (2011) [41] RCT	Within 6 months	12 or 48 weeks	Delayed time to CD4 T-cell count < 350 cells/mm³ after TI
3-drug ART
Hoen, QUEST (2007) [43] Observational prospective	“During primary infection”	48 weeks	During treatment, improved CD4+ T-cell counts, decreased markers of immune activation (CD38 + CD8+ T cells), and decreased proviral DNA
4-drug ART	“During primary infection”	48 weeks